JP2022549495A5 - - Google Patents
Info
- Publication number
- JP2022549495A5 JP2022549495A5 JP2022519147A JP2022519147A JP2022549495A5 JP 2022549495 A5 JP2022549495 A5 JP 2022549495A5 JP 2022519147 A JP2022519147 A JP 2022519147A JP 2022519147 A JP2022519147 A JP 2022519147A JP 2022549495 A5 JP2022549495 A5 JP 2022549495A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- administered
- composition according
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905701P | 2019-09-25 | 2019-09-25 | |
| US62/905,701 | 2019-09-25 | ||
| PCT/US2020/052674 WO2021062122A1 (en) | 2019-09-25 | 2020-09-25 | Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022549495A JP2022549495A (ja) | 2022-11-25 |
| JP2022549495A5 true JP2022549495A5 (enExample) | 2023-10-03 |
| JP7659546B2 JP7659546B2 (ja) | 2025-04-09 |
Family
ID=72915898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022519147A Active JP7659546B2 (ja) | 2019-09-25 | 2020-09-25 | 造血器がんの治療のための抗ｃｄ３０ ａｄｃ、抗ｐｄ－１、および化学療法剤の併用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220347313A1 (enExample) |
| EP (1) | EP4034154A1 (enExample) |
| JP (1) | JP7659546B2 (enExample) |
| KR (1) | KR20220069964A (enExample) |
| CN (1) | CN114728046A (enExample) |
| AU (1) | AU2020351751A1 (enExample) |
| CA (1) | CA3155341A1 (enExample) |
| IL (1) | IL291585A (enExample) |
| MX (1) | MX2022003357A (enExample) |
| WO (1) | WO2021062122A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117241802A (zh) * | 2021-04-21 | 2023-12-15 | 新基公司 | 使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮治疗非霍奇金淋巴瘤的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| EP0582595A1 (en) | 1991-04-26 | 1994-02-16 | Surface Active Limited | Novel antibodies, and methods for their use |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010081004A1 (en) | 2009-01-09 | 2010-07-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| CA2937561A1 (en) * | 2014-01-29 | 2015-08-06 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof |
| MX390955B (es) | 2016-06-02 | 2025-03-19 | Seagen Inc | Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma. |
-
2020
- 2020-09-25 KR KR1020227012445A patent/KR20220069964A/ko not_active Ceased
- 2020-09-25 AU AU2020351751A patent/AU2020351751A1/en not_active Abandoned
- 2020-09-25 US US17/762,867 patent/US20220347313A1/en active Pending
- 2020-09-25 CN CN202080074595.9A patent/CN114728046A/zh active Pending
- 2020-09-25 MX MX2022003357A patent/MX2022003357A/es unknown
- 2020-09-25 EP EP20793200.5A patent/EP4034154A1/en active Pending
- 2020-09-25 WO PCT/US2020/052674 patent/WO2021062122A1/en not_active Ceased
- 2020-09-25 JP JP2022519147A patent/JP7659546B2/ja active Active
- 2020-09-25 CA CA3155341A patent/CA3155341A1/en active Pending
-
2022
- 2022-03-22 IL IL291585A patent/IL291585A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004308749B2 (en) | CD40 antibody formulation and methods | |
| JP2025016606A5 (enExample) | ||
| JP2008540447A5 (enExample) | ||
| JP2011507932A5 (enExample) | ||
| JP2021512107A5 (enExample) | ||
| DE05075555T1 (de) | Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern | |
| TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
| TW201249460A (en) | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of B-cell malignancies symptoms | |
| JP2023508496A5 (enExample) | ||
| JP2023551559A5 (enExample) | ||
| WO2021092134A1 (en) | Dosing regimen for anti-dll3 agents | |
| JP2020536932A5 (enExample) | ||
| JP2023520771A5 (enExample) | ||
| CA2738598C (en) | Composition for treating disease | |
| JP2026001086A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| IL315350A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| JP2021501800A5 (enExample) | ||
| JP2023521853A5 (enExample) | ||
| WO2024199405A1 (zh) | 含抗cd20抗体药物偶联物的药物组合在制备治疗nhl的药物中的用途 | |
| CN112955148A (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| JP3973360B2 (ja) | 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子 | |
| JP2023512084A5 (enExample) | ||
| CN114728046A (zh) | 联合抗cd30 adc、抗pd-1和化疗以治疗血液癌症 | |
| CN112439060B (zh) | Pd-l1免疫疗法的新用途 | |
| RU2023134007A (ru) | Применение конъюгата антитело-лекарственное средство в комбинации с ингибитором иммунных контрольных точек в лечении уротелиального рака |